A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer-Reference-Cited by-同舟云学术

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

Published:2012-12-13 Issue:2 Volume:137 Page:471-482
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Cristofanilli Massimo,Johnston Stephen R. D.,Manikhas Alexey,Gomez Henry L.,Gladkov Oleg,Shao Zhimin,Safina Sufia,Blackwell Kimberly L.,Alvarez Ricardo H.,Rubin Stephen D.,Ranganathan Sulabha,Redhu Suman,Trudeau Maureen E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-2369-x.pdf

Reference30 articles.

1. Cristofanilli M, Buzdar AU, Hortobagyi GN (2003) Update on the management of inflammatory breast cancer. Oncologist 8:141–148

2. Dirix LY, Van Dam P, Prové A, Vermeulen PB (2006) Inflammatory breast cancer: current understanding. Curr Opin Oncol 18:563–571

3. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hasson J, Birnbaum D, Jacquemier J, Viens P (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202(3):265–273

4. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F (2008) Defining the molecular biology of inflammatory breast cancer. Semin Oncol 35(1):41–50

5. Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE (2004) High incidence of HER-2 positivity in inflammatory breast cancer. Breast 13(2):97–103

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer;Journal of Nanobiotechnology;2024-07-20

2. Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-Target EGFR/c-Met Inhibitor;Current Medicinal Chemistry;2024-06-24

3. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation;Pharmacological Research;2023-08

4. Molecular Recognition Study toward the Mitochondrial Electron Transport Chain Inhibitor Mubritinib and Human Serum Albumin;Molecular Pharmaceutics;2023-06-29

5. Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions;Current Topics in Medicinal Chemistry;2022-04